Monopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced Cancers

February 20, 2024

https://www.globenewswire.com/news-release/2024/02/20/2831765/0/en/Monopar-Receives-Clearance-to-Proceed-with-First-in-Human-Phase-1-Trial-of-Novel-Radiopharmaceutical-MNPR-101-Zr-in-Advanced-Cancers.html

WILMETTE, Ill., Feb. 20, 2024 (GLOBE NEWSWIRE) — Monopar Therapeutics Inc. (Nasdaq:MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 dosimetry trial of its novel radiopharmaceutical MNPR-101-Zr.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.